| 于嘉仪,徐滨,王椋.EB病毒阳性的滤泡性淋巴瘤 1例报告并文献复习[J].安徽医药,2025,29(8):1541-1544. |
| EB病毒阳性的滤泡性淋巴瘤 1例报告并文献复习 |
| Epstein-Barr virus-positive follicular lymphoma: a case report and literature review |
| |
| DOI：10.3969/j.issn.1009-6469.2025.08.011 |
| 中文关键词: 淋巴瘤，滤泡性 EB病毒感染 文献复习 抗肿瘤联合化疗方案 预后 |
| 英文关键词: Lymphoma, follicular Epstein-barr virus infections Literature review Antineoplastic combined chemotherapy proto-cols Prognosis |
| 基金项目:山东省医药卫生科技发展计划项目( 20220304045414) |
|
| 摘要点击次数: 782 |
| 全文下载次数: 258 |
| 中文摘要: |
| 目的报告 1例 EB病毒阳性的滤泡性淋巴瘤病例，为该病的诊断、免疫功能评估、治疗及预后提供思路。方法回顾性分析滨州医学院附属胜利油田中心医院于 2023年 12月 7日收治的 1例 EB病毒阳性的滤泡性淋巴瘤病人的临床资料并复习相关文献。结果病人男性， 76岁，临床表现为间断发热、盗汗。根据组织病理学诊断为 EB病毒阳性的滤泡性淋巴瘤，组织学分级: 3A级， Ⅳ期 A，滤泡性淋巴瘤国际预后指数( FLIPI)-1评分 5分， FLIPI-2评分 3分，高危。给予 1个疗程低剂量奥托珠单抗联合环磷酰胺、多柔比星、长春新碱及泼尼松( G-miniCHOP)方案化疗， 3个疗程低剂量奥托珠单抗联合环磷酰胺、多柔比星脂质体、长春新碱及泼尼松( G-mini CDOP)方案化疗，行增强 CT评估疗效为部分缓解。目前仍在治疗中。结论 EB病毒阳性的滤泡性淋巴瘤相对罕见，大多与更具侵袭性的临床病程和高级别转化风险增加相关，疾病进展迅速和总体生存率较差。目前尚无针对 EB病毒阳性的滤泡性淋巴瘤疗效确切的治疗方案。 |
| 英文摘要: |
| Objective To report a case of Epstein-Barr virus (EBV)-positive follicular lymphoma (FL) and provide insights into diag-nosis, immune function assessment, treatment and prognosis.Methods We retrospectively analyzed the clinical data of a patient with EBV-positive FL admitted to Shengli Oilfield Central Hospital Affiliated to Binzhou Medical University on December 7, 2023, and re-viewed relevant literature.Results A 76-year-old male patient presented with intermittent fever and night sweats. Histopathological examination led to a diagnosis of EBV-positive FL (histological grade 3A, stage ⅣA, FLIPI-1 score 5, FLIPI-2 score 3, high risk). The patient underwent one cycle of low-dose obinutuzumab combined with cyclophosphamide, doxorubicin, vincristine, and prednisone (G-miniCHOP), and three cycles of low-dose obinutuzumab combined with cyclophosphamide, liposomal doxorubicin, vincristine, and prednisone (G-miniCDOP). Enhanced CT scan showed a partial response. Treatment was ongoing.Conclusions EBV-positive FL is rare and often associated with an aggressive clinical course, increased risk of high-grade transformation, rapid disease progression, andpoor survival rates. Currently, no definitive treatment regimen exists for this condition. |
|
查看全文
查看/发表评论 下载PDF阅读器 |
| 关闭 |
|
|
|
